ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 2237

Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice

(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

9:00AM-11:00AM: Abstract Number: 2350

Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303; TACI vTD-Fc)

(2326–2351) SLE – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1926

Use of 18F-FDG PET in Assessing Response to Treatment in Adults with Pulmonary Sarcoidosis: A Systematic Literature Review

(1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

9:00AM-11:00AM: Abstract Number: 1890

Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1922

Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol

(1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

9:00AM-11:00AM: Abstract Number: 1855

Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 1911

Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1889

Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2072

Utility of a Novel Pediatric Rheumatology Interactive Teleconference Series: Rheum2Play

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1871

Utility of Infrared Thermography in Patients with Digital Gangrene

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2313

Utilization of Palliative Care in Hospitalized Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Analysis

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2049

Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 2285

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1951

Valid and Reliable Physical Function Tests in Idiopathic Inflammatory Myositis

(1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

9:00AM-11:00AM: Abstract Number: 1958

Validity, Responsiveness and Minimal Clinically Important Difference of EQ-5D-5L in Inflammatory Myositis: A Longitudinal Study

(1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].